Evidence map›Paper›PMID 42004869›Full record

ArticleBioinformatics advances2026

From pathways to prediction: a comparative machine learning framework for prostate cancer survival.

Elif Kardelen Çağdaş, Hüseyin Şan, Berkay Çağdaş, Emre Hafızoğlu

Abstract read
In one paragraph

Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elif Kardelen ÇağdaşInstitute of Biotechnology, Ankara University, Ankara, 06135, Türkiy.ORCID https://orcid.org/0000-0002-5358-3444
Hüseyin ŞanDepartment of Nuclear Medicine, Ankara Bilkent City Hospital, Ankara, 06800, Türkiye.
Berkay ÇağdaşDepartment of Nuclear Medicine, Afyonkarahisar State Hospital, Afyonkarahisar, 03030, Türkiye.
Emre HafızoğluDepartment of Oncology, Afyonkarahisar State Hospital, Afyonkarahisar, 03030, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Prostate cancer shows substantial clinical and molecular heterogeneity, limiting the prognostic accuracy of conventional clinicopathologic models. Single-gene alterations and tumor mutational burden provide limited prognostic discrimination. Pathway-level genomic abstraction may better capture cumulative oncogenic disruption. Results: Genomic and clinical data from 2231 prostate adenocarcinoma patients were analyzed by mapping somatic mutations to 11 cancer-related signaling pathways. A composite pathway-based risk score integrating pathway burden, p53 pathway status, and high-risk co-alterations was developed and evaluated using survival analysis, Cox regression, time-dependent receiver operating characteristic curves, and machine-learning models, with generalizability assessed in an independent external cohort. The score stratified patients into distinct risk groups with significantly different overall survival (log-rank P < .0001); each one-point increase was associated with a 31% higher mortality risk (hazard ratio 1.31, 95% confidence interval 1.21-1.42). The model showed moderate discrimination (concordance index 0.5897) and more stable predictive performance than tumor mutational burden alone. Machine-learning models achieved similar performance, and feature importance analysis identified p53 pathway disruption and pathway burden as key predictors. The proposed framework is a mutation-based genomic risk-stratification tool derived from targeted-sequencing data that provides interpretable prognostic stratification with performance comparable to machine-learning models. Availability and implementation: Available upon request.

Identifiers

PMID42004869
PMCPMC13091648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.